IQ-AI LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.15 GBX | -4.17% |
|
-14.81% | -75.53% |
| 06-14 | IQ-AI Says Brain Cancer Drug Delays Disease Progression in Early-stage Study | MT |
| 06-14 | IQ-AI team begins defining phase 2 protocol for oral gallium maltolate | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 536K 680K 53.59M | Sales 2023 | 609K 774K 60.94M | Capitalization | 8.96M 11.38M 896M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 0 | Net income 2023 | - 0 0 | EV / Sales 2022 | 5.75 x |
| Net cash position 2022 | 252K 320K 25.18M | Net cash position 2023 | 139K 176K 13.88M | EV / Sales 2023 | 14.5 x |
| P/E ratio 2022 |
-6.52
x | P/E ratio 2023 |
-13.8
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.72% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.17% | ||
| 1 week | -14.81% | ||
| Current month | -20.69% | ||
| 1 month | -17.86% | ||
| 3 months | -30.30% | ||
| 6 months | -68.49% | ||
| Current year | -75.53% |
1 week
1.12
1.40
1 month
1.121.60
Current year
1.125.15
1 year
1.125.80
3 years
1.128.98
5 years
1.1223.13
10 years
0.9923.13
| Managers | Title | Age | Since |
|---|---|---|---|
Trevor Brown
CEO | Chief Executive Officer | 78 | 12/02/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Trevor Brown
CEO | Chief Executive Officer | 78 | 12/02/15 |
Vinod Kaushal
BRD | Director/Board Member | 60 | 19/01/17 |
| Director/Board Member | - | 17/12/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/06/24 | 1.15 | -4.17% | 634 234 |
| 17/06/24 | 1.2 | -7.69% | 1,123,732 |
| 14/06/24 | 1.3 | 0.00% | 600,496 |
| 13/06/24 | 1.3 | 0.00% | 212,583 |
| 12/06/24 | 1.3 | -3.70% | 466,219 |
Delayed Quote London S.E., June 18, 2024 at 12:39 pm
More quotes
IQ-AI Limited is a Jersey-based company, which is engaged in the provision of clinical treatments to patients in the field of medical imaging diagnostics, based on technology. The Company operates through two segments: holding company expenses and medical software. Its subsidiaries include Imaging Biometrics, LLC and Stone Checker Software Limited. Imaging Biometrics, LLC is a healthcare imaging software company. In addition to providing regulatory consulting services, Imaging Biometrics, LLC supplies medical technology solutions and has a neuroimaging product portfolio. Stone Checker Software Limited is a supplier of technology solutions in the field of kidney stone analysis and kidney stone prevention.
Calendar
15/09/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -75.53% | 3.38M | |
| -17.74% | 8.18B | |
| +68.25% | 4.32B | |
| +5.67% | 2.74B | |
| -2.98% | 2.62B | |
| -51.24% | 1.95B | |
| -19.04% | 1.67B | |
| -22.78% | 1.41B | |
| +16.69% | 1.2B | |
| -44.81% | 1.12B |
- Stock Market
- Equities
- IQAI Stock
